Can I stop taking Pemetinib once I start taking it? What are the effects after stopping the medication?

Pemigatinib is a targeted drug targeting FGFR2 gene mutations. It is mainly used to treat tumors related to FGFR2 gene mutations such as advanced biliary cancer. It prevents the growth and division of tumor cells by inhibiting the FGFR2 signaling pathway. During treatment, patients may consider discontinuing treatment due to side effects, disease remission, or other clinical factors. However, the consequences of drug discontinuation require consideration of multiple factors, as the therapeutic efficacy of pemetinib is often dependent on continued administration.

If the drug is stopped suddenly during treatment, tumor recurrence or disease progression may occur. Pemetinib can effectively control the disease by inhibiting the proliferation and spread of tumor cells. After discontinuation of medication, especially without appropriate transition and physician guidance, tumors may become reactivated, leading to worsening of the disease. In addition, the response after stopping the drug varies depending on the patient's specific situation, and some patients may experience recurrence of symptoms or even more serious side effects.

If the patient decides to discontinue medication due to side effects or other reasons, the patient should gradually reduce the dose of the medication under the guidance of a doctor rather than stopping use suddenly. Doctors will develop an appropriate discontinuation plan based on the patient's condition and drug resistance to reduce possible side effects and risks caused by discontinuation of medication. Clinically, doctors usually evaluate the timing of drug discontinuation, monitor changes in condition, and adopt corresponding treatment strategies based on the patient's response to ensure the best treatment effect.

Pemetinib is an important targeted drug that can effectively control cancers with specific genetic mutations, but caution needs to be taken when discontinuing the drug. If patients are considering discontinuing medication, they should communicate closely with their doctors to develop an appropriate discontinuation strategy based on their individual treatment response and condition. The impact after discontinuation of medication varies depending on the patient's specific situation. Discontinuation of medication may lead to tumor recurrence or worsening of symptoms, so it must be handled with caution to ensure that the patient's treatment effect and health status receive continued attention.

Reference materials:https://go.drugbank.com/drugs/DB15102